»5 Minute Wrap Up by Equitymaster

On This Day - 26 SEPTEMBER 2018
This Repeating Pattern in the Market Offers Quality Stocks at Great Prices

Kunal Thanvi, Research analyst

Dear reader, have you noticed a repeating pattern in the market over the last few days?

It's the pattern of completely unrelated stocks suffering from some kind of government/regulatory action.

First, Sarvajeet highlighted the issues faced by PVR and Inox and how the prices of expensive food items in multiplexes have come under the scanner.

Then, it was my turn. I wrote about how the Mumbai municipality asked Nesco to stop all events/exhibition due to traffic issues. (This issue seems to be settled for now.)

Last week, the market regulator, Securities and Exchange Board of India (SEBI), cut the total expense ratio (TER) charged by mutual funds.

In simple words, TER is a percentage of a mutual fund scheme's corpus that the fund house charges towards expenses. These include administrative and fund management costs.

The revised TER slab structure for mutual funds will reduce earnings of AMCs by around 15-20%.

Reduction in Total Expense Ratio

Equity MF AUM
(In Rs billion)
Newly imposed TER Average TER so far
0-5 2.25% 2.40%
5-7.5 2% 2.51%
7.5-20 1.75% 2.21%
20-50 1.60% 2.08%
50-100 1.50% 2.07%
100-500 Reduction of 0.05% for
increase of Rs 50 billion AUM
> 500 1.05%  
Data Source: SEBI, Bloomberg Quint

The stocks of asset management companies have collapsed like a pack of cards. Since the announcement, the stocks of HDFC AMC and Reliance Nippon Life are down 10% and 20% respectively.

--- Advertisement ---
How to Add This Investing Book to Your Collection…Virtually for FREE

Equitymaster's Secrets :: Our Biggest Lessons From Over Two Decades Of Investing Journey
We just published Equitymaster's Secrets: 2018 Limited Edition – our collection of insights and secrets from over 20 years of successful investing.

We believe every serious investor should have a copy of this book on their bookshelf.

Now, normally an earlier edition of this book sells on Amazon for Rs 1,450.

But as an Equitymaster reader – you have the chance to claim a virtually free copy of this book, and have it delivered to your home, anywhere in India.

You'll find all the details here.

The mutual fund advertisement says, 'Mutual fund investments are subject to market risks. Please read all offer documents carefully before investing'.

Advertisements for investing in AMC companies should say, 'AMC stocks are subject to market as well as unforeseen regulatory risks. Please check the valuations carefully before investing'.

Just a few weeks back, HDFC AMC's IPO received a great response and the stock had a stellar debut.

At the upper end of the price band, HDFC AMC was valued at over 31 times its FY18 earnings at the time of the IPO. That seemed quite expensive to us.

We published an Avoid view on the IPO.

This is what Tanushree said in the IPO note...

  • The company also faces many regulatory risks such as tightening of fees and commissions, cap on fund expenses, recategorization of schemes, etc.by the market regulator. Any such events can have a substantial effect on the business of the company and affect its profitability.

In the concluding remarks, she wrote:

  • Clearly, the valuations are on the higher side, even if one considers a fairly aggressive growth trajectory in AUM over the next few years.

    We believe that despite the strong fundamentals and growth potential of the business, the IPO price exposes investors to steep valuation risks.

    In our view, therefore, the issue should be avoided.

The other AMC stock Reliance Nippon Life is trading below its issue price. During the IPO, its valuations too were steep (about 37 times its FY17 earnings.)

Despite the long-term tailwinds in terms of financialisation of savings and under-penetrated mutual fund market in India, we gave a pass to both the IPOs.

Clearly, it boiled down to steep valuations.

--- Advertisement ---
Whatever You Do…Don't Buy This Book from Amazon!

Equitymaster's Secrets :: Our Biggest Lessons From Over Two Decades Of Investing Journey
Equitymaster's Secrets is one of the most popular books we've ever published. It contains investing insights and secrets you probably won't find anywhere else in the world.

It also contains some of our most valuable, and closely guarded, investing strategies – strategies that have lead to some of our most successful multi-bagger finds to date.

Now, this book is available on Amazon for Rs 1,450…but as one of our loyal readers, we don't believe you shouldn't have to pay for the book.

Instead, we'll send over a virtually FREE copy of the latest edition of this book…right to your house (anywhere in India)!

All you have to do is cover postage and handling – and of course, share your Indian postal address with us.

Click here to claim your book.

Instead of recommending such risky AMC stocks, Tanushree did something much better.

She waited for the right opportunity.

And sure enough... an opportunity presented itself last Friday during the crazy sell-off in the market.

She recommended a stock with an upside of more than 50% to her StockSelect subscribers.

In investing, there will always be some uncertainty. You can't escape it. But uncertainty brings with it opportunity.

On this journey, you need to prepare for unforeseen risks And be prepared to grab the opportunities when the present themselves.

You can do this by investing with a margin of safety.

As Seth Klarman says...

  • A margin of safety is achieved when securities are purchased at prices sufficiently below underlying value to allow for human error, bad luck, or extreme volatility in a complex, unpredictable and rapidly changing world.

Happy and Safe Investing!

Chart of the Day

Talking about margin of safety, till now, I didn't recommend a pharma stock to my Smart Money Secrets Subscribers. One of the main reasons was a lack of clarity.

But this month, I recommended my first pharma stock.

One of my favourite super investors has bought a 0.5% stake in the company. I believe he will scale it up in time.

My Pharma Recommendation is Growing Faster than the Industry

The stock needs to correct a bit before I can give an outright buy. When it does, I'll inform Smart Money Secrets subscribers via a special report.

Don't miss out on opportunities like this, dear reader. If you haven't signed up for Smart Money Secrets, you can do so here.


Kunal Thanvi
Kunal Thanvi (Research Analyst)
Editor, Smart Money Secrets

PS: Kunal Thanvi, editor of Smart Money Secrets, is the Sherlock Holmes of investing. He is on a mission to reveal the top picks of India's best investors to you. For clean, high quality stock recommendations that won't put your wealth at risk, subscribe to Kunal's Smart Money Secrets.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.

Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement

Disclosure & Disclaimer: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. The Author does not hold any shares in the company/ies discussed in this document. Equitymaster may hold shares in the company/ies discussed in this document under any of its other services.

This document is confidential and is supplied to you for information purposes only. It should not (directly or indirectly) be reproduced, further distributed to any person or published, in whole or in part, for any purpose whatsoever, without the consent of Equitymaster.

This document is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity, who is a citizen or resident or located in any locality, state, country or other jurisdiction, where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Equitymaster or its affiliates to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, Canada or the European Union countries, the same may be ignored.

This document does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Our research recommendations are general in nature and available electronically to all kind of subscribers irrespective of subscribers' investment objectives and financial situation/risk profile. Before acting on any recommendation in this document, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the securities referred to in this material and the income from them may go down as well as up, and subscribers may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. Information herein is believed to be reliable but Equitymaster and its affiliates do not warrant its completeness or accuracy. The views/opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time without notice. This document should not be construed as an offer to sell or solicitation of an offer to buy any security or asset in any jurisdiction. Equitymaster and its affiliates, its directors, analyst and employees will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any decisions based on this document.

As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407